Effectiveness of pandemic and seasonal influenza vaccines in preventing laboratory-confirmed influenza in Adults: A clinical cohort study during epidemic seasons 2009-2010 and 2010-2011 in Finland

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Syrjänen, Ritva K ^a   Jokinen, Jukka ^a   Ziegler, Thedi ^a   Sundman, Jonas ^a   Lahdenkari, Mika ^a   Julkunen, Ilkka ^a,b   Kilpi, Terhi M ^a  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; VIRUS RNA;

2009 H1N1 INFLUENZA; ADULT; AGED; ARTICLE; COHORT ANALYSIS; DRUG EFFICACY; FEMALE; FEVER; FINLAND; FOLLOW UP; HUMAN; INFLUENZA B; INFLUENZA VACCINATION; LABORATORY DIAGNOSIS; MALE; MEDICAL RECORD; NOSE SMEAR; ORAL BIOPSY; PANDEMIC INFLUENZA; PNEUMONIA; PROSPECTIVE STUDY; RESPIRATORY TRACT INFECTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEASONAL INFLUENZA; SYMPTOMATOLOGY; ADOLESCENT; CLINICAL TRIAL; IMMUNOLOGY; INFLUENZA A VIRUS (H1N1); INFLUENZA, HUMAN; MIDDLE AGED; VACCINATION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; COHORT STUDIES; FEMALE; FINLAND; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; VACCINATION; YOUNG ADULT;

EID: 84907494541     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0108538     Document Type: Article

References (46)

1. Van Kerkhove MD, Hirve S, Koukounari A, Mounts AW, H1N1pdm serology working group (2013) Estimating age-specific cumulative incidence for the 2009 influenza pandemic: A meta-analysis of A(H1N1)pdm09 serological studies from 19 countries. Influenza Other Respi Viruses 7: 872-886
2. Presanis AM, Pebody RG, Paterson BJ, Tom BD, Birrell PJ, et al. (2011) Changes in severity of 2009 pandemic A/H1N1 influenza in England: A Bayesian evidence synthesis. BMJ 343:d5408
3. Chowell G, Echevarria-Zuno S, Viboud C, Simonsen L, Tamerius J, et al. (2011) Characterizing the epidemiology of the 2009 influenza A/H1N1 pandemic in Mexico. PLoS Med 8:e1000436
4. Dawood FS, Iuliano AD, Reed C, Meltzer MI, Shay DK, et al. (2012) Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: A modelling study. Lancet Infect Dis 12: 687-695
5. Molbak K, Widgren K, Jensen KS, Ethelberg S, Andersen PH, et al. (2011) Burden of illness of the 2009 pandemic of influenza A (H1N1) in Denmark. Vaccine 29 Suppl 2:B63-69
6. Ikonen N, Strengell M, Kinnunen L, Osterlund P, Pirhonen J, et al. (2010) High frequency of cross-reacting antibodies against 2009 pandemic influenza A(H1N1) virus among the elderly in Finland. Euro Surveill 15: 19478
7. Lyytikainen O, Kuusi M, Snellman M, Virtanen M, Eskola J, et al. (2011) Surveillance of influenza in Finland during the 2009 pandemic, 10 May 2009 to 8 March 2010. Euro Surveill 16: 19908
8. Hulkko T, Lyytikäinen O, Jaakola S, Kuusi M, Puumala J, et al, editors (2011) Infectious Diseases in Finland 2010. Report 39/2011 National Institute for Health and Welfare. Tampere: Juvenes Print. pp. 7-8
9. Jacks A, Ollgren J, Ziegler T, Lyytikainen O (2012) Influenza-associated hospitalisations in Finland from 1996 to 2010: unexpected age-specific burden during the influenza A(H1N1)pdm09 pandemic from 2009 to 2010. Euro Surveill 17: 20276
10. Lyytikäinen O, Kuusi M, Toikkanen S, Virtanen MJ, Rönkkö E, et al. (2011) Influenssa A(H1N1) 2009 -pandemian toinen epidemia-aalto aiheutti vähemmän kuolemia ja tehohoidon tarvetta. Suomen Lääkärilehti 66: 2925-2930. Finnish.
11. Valenciano M, Kissling E, Cohen JM, Oroszi B, Barret AS, et al. (2011) Estimates of pandemic influenza vaccine effectiveness in Europe, 2009-2010: results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) multicentre case-control study. PLoS Med 8:e1000388
12. Griffin MR, Monto AS, Belongia EA, Treanor JJ, Chen Q, et al. (2011) Griffin MR, Monto AS, Belongia EA, et al. Effectiveness of non-adjuvanted pandemic influenza A vaccines for preventing pandemic influenza acute respiratory illness visits in 4 U.S. communities. PLoS One 6:e23085
13. Simpson CR, Ritchie LD, Robertson C, Sheikh A, McMenamin J (2010) Vaccine effectiveness in pandemic influenza - primary care reporting (VIPER): An observational study to assess the effectiveness of the pandemic influenza A (H1N1)v vaccine. Health Technol Assess 14: 313-346
14. Hardelid P, Fleming DM, McMenamin J, Andrews N, Robertson C, et al. (2011) Effectiveness of pandemic and seasonal influenza vaccine in preventing pandemic influenza A(H1N1)2009 infection in England and Scotland 2009- 2010. Euro Surveill 16: 19763
15. Wichmann O, Stocker P, Poggensee G, Altmann D, Walter D, et al. (2010) Pandemic influenza A(H1N1) 2009 breakthrough infections and estimates of vaccine effectiveness in Germany 2009-2010. Euro Surveill 15: 19561
16. Uphoff H, An der Heiden M, Schweiger B, Campe H, Beier D, et al. (2011) Effectiveness of the AS03-adjuvanted vaccine against pandemic influenza virus A/(H1N1) 2009-a comparison of two methods; Germany, 2009/10. PLoS One 6:e19932
17. Örtqvist Å , Berggren I, Insulander M, de Jong B, Svenungsson B (2011) Effectiveness of an adjuvanted monovalent vaccine against the 2009 pandemic strain of influenza A(H1N1)v, in Stockholm County, Sweden. Clin Infect Dis 52: 1203-1211
18. Costa JT, Silva R, Tavares M, Nienhaus A (2012) High effectiveness of pandemic influenza A (H1N1) vaccination in healthcare workers from a Portuguese hospital. Int Arch Occup Environ Health 85: 747-752
19. Skowronski DM, Janjua NZ, De Serres G, Hottes TS, Dickinson JA, et al. (2011) Effectiveness of AS03 adjuvanted pandemic H1N1 vaccine: case-control evaluation based on sentinel surveillance system in Canada, autumn 2009. BMJ 342:c7297
20. Castilla J, Moran J, Martinez-Artola V, Fernandez-Alonso M, Guevara M, et al. (2011) Effectiveness of the monovalent influenza A(H1N1)2009 vaccine in Navarre, Spain, 2009-2010: cohort and case-control study. Vaccine 29: 5919-5924
21. Savulescu C, Jimenez-Jorge S, de Mateo S, Pozo F, Casas I, et al. (2011) Using surveillance data to estimate pandemic vaccine effectiveness against laboratory confirmed influenza A(H1N1)2009 infection: Two case-control studies, Spain, season 2009-2010. BMC Public Health 11: 899
22. Bateman AC, Kieke BA, Irving SA, Meece JK, Shay DK, et al. (2013) Effectiveness of monovalent 2009 pandemic influenza A virus subtype H1N1 and 2010-2011 trivalent inactivated influenza vaccines in Wisconsin during the 2010-2011 influenza season. J Infect Dis 207: 1262-1269
23. Skowronski DM, Janjua NZ, De Serres G, Winter AL, Dickinson JA, et al. (2012) A sentinel platform to evaluate influenza vaccine effectiveness and new variant circulation, Canada 2010-2011 season. Clin Infect Dis 55: 332-342
24. Pebody R, Hardelid P, Fleming D, McMenamin J, Andrews N, et al. (2011) Effectiveness of seasonal 2010/11 and pandemic influenza A(H1N1)2009 vaccines in preventing influenza infection in the United Kingdom: mid-season analysis 2010/11. Euro Surveill 16: 19791
25. Englund H, Campe H, Hautmann W (2013) Effectiveness of trivalent and monovalent influenza vaccines against laboratory-confirmed influenza infection in persons with medically attended influenza-like illness in Bavaria, Germany, 2010/2011 season. Epidemiol Infect 141: 1807-1815
26. Fielding JE, Grant KA, Garcia K, Kelly HA (2011) Effectiveness of seasonal influenza vaccine against pandemic (H1N1) 2009 virus, Australia, 2010. Emerg Infect Dis 17: 1181-1187
27. Jimenez-Jorge S, Savulescu C, Pozo F, de Mateo S, Casas I, et al. (2012) Effectiveness of the 2010-11 seasonal trivalent influenza vaccine in Spain: cycEVA study. Vaccine 30: 3595-3602
28. Kissling E, Valenciano M, Cohen JM, Oroszi B, Barret AS, et al. (2011) IMOVE multi-centre case control study 2010-11: overall and stratified estimates of influenza vaccine effectiveness in Europe. PLoS One 6:e27622
29. Widgren K, Magnusson M, Hagstam P, Widerstrom M, Ortqvist A, et al. (2013) Prevailing effectiveness of the 2009 influenza A(H1N1)pdm09 vaccine during the 2010/11 season in Sweden. Euro Surveill 18: 20447
30. Nohynek H, Jokinen J, Partinen M, Vaarala O, Kirjavainen T, et al. (2012) AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS One 7:e33536
31. Walker WT, Faust SN (2010) Monovalent inactivated split-virion AS03- adjuvanted pandemic influenza A (H1N1) vaccine. Expert Rev Vaccines 9: 1385-1398
32. European Commission (2009) European Commission Decision 2009/363/EC. Official Journal of the European Union L 110/58
33. Rönkkö E, Ikonen N, Kontio M, HaanpääM, Kallio-Kokko H, et al. (2011) Validation and diagnostic application of NS and HA gene-specific real-time reverse transcription-PCR assays for detection of 2009 pandemic influenza A (H1N1) viruses in clinical specimens. J Clin Microbiol 49: 2009-2011
34. R Development Core Team (2013) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, URL http://www.R-project.org/
35. Manzoli L, De Vito C, Salanti G, D'Addario M, Villari P, et al. (2011) Metaanalysis of the immunogenicity and tolerability of pandemic influenza A 2009 (H1N1) vaccines. PLoS One 6:e24384
36. Mahmud S, Hammond G, Elliott L, Hilderman T, Kurbis C, et al. (2011) Effectiveness of the pandemic H1N1 influenza vaccines against laboratoryconfirmed H1N1 infections: population-based case-control study. Vaccine 29: 7975-7981
37. Guzman Herrador BR, Aavitsland P, Feiring B, Riise Bergsaker MA, Borgen K (2012) Usefulness of health registries when estimating vaccine effectiveness during the influenza A(H1N1)pdm09 pandemic in Norway. BMC Infect Dis 12: 63
38. European Centre for Disease Prevention and Control (ECDC) (2011) Seasonal Influenza 2010-2011 in Europe (EU/EEA countries). Stockholm: ECDC. p 10. Available at: http://ecdc.europa.eu/en/publications/publications/110125-ra-seasonal-influenza-eu-eea-2010-2011.pdf. Accessed 3 September 2013
39. Gilmour H, Hofmann N (2010) H1N1 vaccination. Health Rep 21: 63-69
40. Emborg HD, Krause TG, Hviid A, Simonsen J, Molbak K (2011) Effectiveness of vaccine against pandemic influenza A/H1N1 among people with underlying chronic diseases: cohort study, Denmark, 2009-10. BMJ 344:d7901
41. Kavanagh K, Robertson C, McMenamin J (2013) Estimates of influenza vaccine effectiveness in primary care in Scotland vary with clinical or laboratory endpoint and method-Experience across the 2010/11 season. Vaccine 31: 4556-4563
42. Shubin M, Virtanen M, Toikkanen S, Lyytikäinen O, Auranen K (2014) Estimating the burden of A(H1N1)pdm09 influenza in Finland during two seasons. Epidemiol Infect 142: 964-974
43. Mytton OT, Rutter PD, Donaldson LJ (2012) Influenza A(H1N1)pdm09 in England, 2009 to 2011: A greater burden of severe illness in the year after the pandemic than in the pandemic year. Euro Surveill 17: 20139
44. Orsted I, Molvadgaard M, Nielsen HL, Nielsen H (2013) The first, second and third wave of pandemic influenza A (H1N1)pdm09 in North Denmark Region 2009-2011: A population-based study of hospitalizations. Influenza Other Respir Viruses 7: 776-782
45. Chuang JH, Huang AS, Huang WT, Liu MT, Chou JH, et al. (2012) Nationwide surveillance of influenza during the pandemic (2009-10) and postpandemic (2010-11) periods in Taiwan. PLoS One 7:e36120
46. Athanasiou M, Baka A, Andreopoulou A, Spala G, Karageorgou K, et al. (2011) Influenza surveillance during the post-pandemic influenza 2010/11 season in Greece, 04 October 2010 to 22 May 2011. Euro Surveill 16: 20004.